VEZF1
protein-codingvascular endothelial zinc finger 1, the group of Zinc fingers C2H2-type
Gene summary
Transcriptional regulatory proteins containing tandemly repeated zinc finger domains are thought to be involved in both normal and abnormal cellular proliferation and differentiation. ZNF161 is a C2H2-type zinc finger protein (Koyano-Nakagawa et al., 1994 [PubMed 8035792]). See MIM 603971 for general information on zinc finger proteins.[supplied by OMIM, Sep 2008]
- ZNF161
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~16.7 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0859381
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0859381
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0005258
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0859381
Submitter: ClinGen
The VEZF1gene was evaluated for autosomal dominant dilated cardiomyopathy (DCM). VEZF1 is a transcriptional regulatory protein that is expressed in human heart tissue (PMID: 15882861). Inactivation of Vezf1 results in embryonic lethality in the mouse caused by angiogenic remodeling defects and loss of vascular integrity in homozygous mutant embryos (PMID: 15882861). Knockout of Vezf1 in zebrafish caused increased pericardial cavity size and decreased the number and size of ventricular cardiomyocytes and showed no hemodynamic stress-induced increase in cardiac growth and contractile function (PMID: 31911272). RNA sequencing, qRT-PCR and Western blot analysis showed that VEZF1 knockout significantly lowers β-myosin heavy chain (β-MHC/Myh7) expression and downregulated other key genes in cardiac systolic function (PMID: 31911272). Publications that presented genetic evidence were excluded due to DCM GCEP concerns of suspect data in accordance with other publications from this author group as described in the DCM GCEP Specification Document (Shi et al., 2023, PMID: 36657711). No convincing evidence for a causal role for VEZF1 for AD DCM has been reported. Although this gene-disease assertion is supported by expression and protein interaction studies, no reports have directly implicated this gene in humans. This classification was approved by the ClinGen Dilated Cardiomyopathy Working Group on 01/10/2025 (SOP Version 10).
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular
Intervention: Cardiovascular
Rationale: The condition may involve increased risk of cardiomyopathy, and awareness may allow early identification and management of cardiac disease
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to VEZF1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_007146.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 2 | 2 | ||||
| missense | 41 | 41 | ||||
| nonsense | 1 | 2 | 3 | |||
| start loss | 0 | |||||
| frameshift | 2 | 2 | ||||
| splice donor/acceptor (+/-2bp) | 2 | 2 | ||||
| Total | 1 | 0 | 45 | 4 | 0 | 50 |
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_009077.2 | 6 | MANE Select | |
| Ensembl | ENSP00000462337.1 | 6 | MANE Select | |
| RefSeq | NP_001317322.1 | 6 | Standard | |
| Ensembl | ENSP00000258963.3 | 5 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Biological Process
- angiogenesis
- endothelial cell development
- regulation of transcription by RNA polymerase II
- transcription by RNA polymerase II
- cellular defense response
Molecular Function
- RNA polymerase II regulatory region sequence-specific DNA binding
- DNA-binding transcription factor activity, RNA polymerase II-specific
- DNA-binding transcription activator activity, RNA polymerase II-specific
- metal ion binding
Cellular Component
- nucleoplasm
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000581208
- Coding exons
- 6
- Length
- 16711
- Individuals with no LoFs
- 125656
- Homozygous LoFs
- 18
- Heterozygous LoFs
- 48
- Defined
- 125722
- p
- 0.000263
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 2.92 | 148 | 287 | 0.515 | 0.0000149 | 3426 |
| Missense (PolyPhen) | 29 | 84.158 | 0.34459 | 1018 | ||
| Synonymous | -1.38 | 126 | 108 | 1.17 | 0.00000584 | 1041 |
| Loss of Function | 3.91 | 1 | 19.7 | 0.0507 | 0.00000108 | 230 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.0019 | 0.0010 | notable |
| Latino/Admixed American | 0.000093 | 0.000058 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00022 | 0.00016 | rare |
| Finnish | 0.00061 | 0.00028 | rare |
| European (Non-Finnish) | 0.00028 | 0.00014 | rare |
| South Asian | 0.0015 | 0.00072 | notable |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Possible transcription factor. Specifically binds to the CT/GC-rich region of the interleukin-3 promoter and mediates tax transactivation of IL-3. {ECO:0000269|PubMed:8035792}.;
Recessive Scores
- pRec
- 0.122
Intolerance Scores
- LoFtool
- 0.246
- RVIS EVS
- -0.65
- RVIS percentile EVS
- 16.36
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- S
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.646
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |